Difference between revisions of "Eculizumab (Soliris)"
Jump to navigation
Jump to search
(updated content) |
|||
| Line 1: | Line 1: | ||
==General information== | ==General information== | ||
| − | Class/mechanism: Complement inhibitor; monoclonal antibody that binds to complement protein C5, preventing its cleavage to C5a and C5b and the formation of the terminal complement complex C5b-9. Eculizumab is used in diseases involving abnormal complement-mediated activity, such as paroxysmal nocturnal hemoglobinuria (PNH)and complement-mediated thrombotic microangiopathy (TMA) in patients with atypical hemolytic uremic syndrome (aHUS).<ref name="insert">[http://www.soliris.net/indications/soliris_pi.pdf Eculizumab (Soliris) package insert]</ref><ref>[ | + | Class/mechanism: Complement inhibitor; monoclonal antibody that binds to complement protein C5, preventing its cleavage to C5a and C5b and the formation of the terminal complement complex C5b-9. Eculizumab is used in diseases involving abnormal complement-mediated activity, such as paroxysmal nocturnal hemoglobinuria (PNH)and complement-mediated thrombotic microangiopathy (TMA) in patients with atypical hemolytic uremic syndrome (aHUS).<ref name="insert">[http://www.soliris.net/indications/soliris_pi.pdf Eculizumab (Soliris) package insert]</ref><ref>[[Media:Eculizumab.pdf | Eculizumab (Soliris) package insert (locally hosted backup)]]</ref><ref>[http://soliris.net Soliris manufacturer's website]</ref> |
<br>Route: IV | <br>Route: IV | ||
<br>Extravasation: no information | <br>Extravasation: no information | ||
| Line 6: | Line 6: | ||
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as [http://www.thomsonhc.com/home/dispatch Micromedex], [http://online.lexi.com/ Lexicomp], [http://reference.medscape.com/drug/soliris-eculizumab-342875 Medscape], [http://www.utdol.com/online/content/search.do UpToDate (courtesy of Lexicomp)], or the prescribing information.<ref name="insert"></ref> | For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as [http://www.thomsonhc.com/home/dispatch Micromedex], [http://online.lexi.com/ Lexicomp], [http://reference.medscape.com/drug/soliris-eculizumab-342875 Medscape], [http://www.utdol.com/online/content/search.do UpToDate (courtesy of Lexicomp)], or the prescribing information.<ref name="insert"></ref> | ||
| + | |||
| + | ==Diseases for which it is used== | ||
| + | *Paroxysmal nocturnal hemoglobinuria (PNH) | ||
| + | *Atypical hemolytic-uremic syndrome (aHUS) | ||
==Patient drug information== | ==Patient drug information== | ||
| + | *[http://www.soliris.net/indications/soliris_pi.pdf#page=7 Eculizumab (Soliris) package insert pages 7-8]<ref name="insert"></ref> | ||
| + | *Brief patient counseling information can be found on [http://www.soliris.net/indications/soliris_pi.pdf#page=6 page 6 of the package insert]<ref name="insert"></ref> | ||
| + | *[http://chemocare.com/chemotherapy/drug-info/eculizumab.aspx Eculizumab (Soliris) patient drug information (Chemocare)]<ref>[http://chemocare.com/chemotherapy/drug-info/eculizumab.aspx Eculizumab (Soliris) patient drug information (Chemocare)]</ref> | ||
*[http://www.uptodate.com/contents/eculizumab-patient-drug-information Eculizumab (Soliris) patient drug information (UpToDate)]<ref>[http://www.uptodate.com/contents/eculizumab-patient-drug-information Eculizumab (Soliris) patient drug information (UpToDate)]</ref> | *[http://www.uptodate.com/contents/eculizumab-patient-drug-information Eculizumab (Soliris) patient drug information (UpToDate)]<ref>[http://www.uptodate.com/contents/eculizumab-patient-drug-information Eculizumab (Soliris) patient drug information (UpToDate)]</ref> | ||
==References== | ==References== | ||
<references/> | <references/> | ||
| + | |||
| + | [[Category:Drug index]] | ||
| + | [[Category:Antibody medications]] | ||
| + | [[Category:Hematology medications]] | ||
Revision as of 05:13, 15 October 2012
General information
Class/mechanism: Complement inhibitor; monoclonal antibody that binds to complement protein C5, preventing its cleavage to C5a and C5b and the formation of the terminal complement complex C5b-9. Eculizumab is used in diseases involving abnormal complement-mediated activity, such as paroxysmal nocturnal hemoglobinuria (PNH)and complement-mediated thrombotic microangiopathy (TMA) in patients with atypical hemolytic uremic syndrome (aHUS).[1][2][3]
Route: IV
Extravasation: no information
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, Medscape, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Diseases for which it is used
- Paroxysmal nocturnal hemoglobinuria (PNH)
- Atypical hemolytic-uremic syndrome (aHUS)
Patient drug information
- Eculizumab (Soliris) package insert pages 7-8[1]
- Brief patient counseling information can be found on page 6 of the package insert[1]
- Eculizumab (Soliris) patient drug information (Chemocare)[5]
- Eculizumab (Soliris) patient drug information (UpToDate)[6]
References
- ↑ 1.0 1.1 1.2 1.3 Eculizumab (Soliris) package insert
- ↑ Eculizumab (Soliris) package insert (locally hosted backup)
- ↑ Soliris manufacturer's website
- ↑ Soliris Risk Evaluation and Mitigation Strategy (REMS) Site
- ↑ Eculizumab (Soliris) patient drug information (Chemocare)
- ↑ Eculizumab (Soliris) patient drug information (UpToDate)